Literature DB >> 8736275

Peripheral glucose metabolism in human hyperprolactinaemia.

M C Foss1, F J Paula, G M Paccola, C E Piccinato.   

Abstract

OBJECTIVE: Prolactin has important biological actions in several species which include metabolic control and water/electrolyte balance. However, human PRL has generally been characterized as a mammotrophic hormone and it is unknown whether PRL has any important metabolic actions. This study was thus conducted to evaluate the effect of hyperprolactinaemia on peripheral muscle glucose metabolism.
DESIGN: The study was designed to determine forearm muscle glucose uptake and utilization (oxidative and non-oxidative metabolism) in normal and hyperprolactinaemic subjects in the post-absorptive state and for 3 hours after the ingestion of 75 g of glucose. Peripheral glucose metabolism was analysed by the forearm technique to estimate muscle exchange of substrates combined with local indirect calorimetry. PATIENTS: Eight hyperprolactinaemic patients (HP group, 6 females and 2 males) and ten normal subjects (N group, 7 females and 3 males) were studied. The hyperprolactinaemic patients showed no clinical or laboratory evidence of acromegaly or hypothyroidism and were not using any PRL releasing drugs. MEASUREMENTS: Forearm blood flow was measured by capacitance plethysmography and arterial and venous blood samples were drawn simultaneously to determine plasma glucose, serum FFA, total blood CO2 and O2 and serum insulin in the post-absorptive state (0 time) and at 30, 60, 120 and 180 minutes after glucose ingestion.
RESULTS: No significant difference in glucose uptake by the forearm muscle tissue was observed between the N and HP groups (823 +/- 103 vs 828 +/- 110 mumol/100 ml forearm 3 h, respectively), nor were any significant differences observed in the intracellular utilization of glucose (oxidative and non-oxidative metabolism). However, the serum insulin levels after glucose ingestion were significantly higher in hyperprolactinaemic patients than in normal subjects, especially at 30 (N 283 +/- 46 vs HP 581 +/- 133 pmol/l) and 60 minutes (N 291 +/- 37 vs HP 544 +/- 61 pmol/l). Furthermore, after glucose ingestion the suppression of serum FFA levels was smaller in the hyperprolactinaemic patients than in normal subjects.
CONCLUSIONS: This study demonstrated that insulin resistance is associated with the presence of spontaneous human hyperprolactinaemia. The hyperinsulinaemia detected in the hyperprolactinaemic patients after the oral glucose stimulus did not determine a proportional increase in forearm glucose uptake and utilization, which were similar to the normal levels. The suppression of serum free fatty acid concentrations was also smaller in hyperprolactinaemic patients during the oral glucose challenge, suggesting an impaired antilipolytic effect of insulin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8736275     DOI: 10.1111/j.1365-2265.1995.tb00541.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  11 in total

1.  Macroprolactinemia, like hyperprolactinemia, may promote platelet activation.

Authors:  Inan Anaforoglu; Melek Eda Ertorer; Ilknur Kozanoglu; Birsel Unal; Filiz Eksi Haydardedeoglu; Okan Bakiner; Emre Bozkirli; Neslihan Bascil Tutuncu; Nilgun Guvener Demirag
Journal:  Endocrine       Date:  2010-02-03       Impact factor: 3.633

2.  Insulin sensitivity and hyperprolactinemia.

Authors:  A Tuzcu; M Bahceci; M Dursun; C Turgut; S Bahceci
Journal:  J Endocrinol Invest       Date:  2003-04       Impact factor: 4.256

3.  Evaluation of insulin sensitivity in hyperprolactinemic subjects by euglycemic hyperinsulinemic clamp technique.

Authors:  Alpaslan Tuzcu; Serkan Yalaki; Senay Arikan; Deniz Gokalp; Mithat Bahcec; Sadiye Tuzcu
Journal:  Pituitary       Date:  2009-05-01       Impact factor: 4.107

4.  The interplay of prolactin and the glucocorticoids in the regulation of beta-cell gene expression, fatty acid oxidation, and glucose-stimulated insulin secretion: implications for carbohydrate metabolism in pregnancy.

Authors:  Ramamani Arumugam; Eric Horowitz; Danhong Lu; J Jason Collier; Sarah Ronnebaum; Don Fleenor; Michael Freemark
Journal:  Endocrinology       Date:  2008-07-03       Impact factor: 4.736

Review 5.  The effects of hyperprolactinemia on bone and fat.

Authors:  Amal Shibli-Rahhal; Janet Schlechte
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

6.  Prolactin and sex steroids levels in congenital lifetime isolated GH deficiency.

Authors:  Menilson Menezes; Roberto Salvatori; Luiza D Melo; Ívina E S Rocha; Carla R P Oliveira; Rossana M C Pereira; Anita H O Souza; Eugênia H O Valença; Enaldo V Melo; Viviane C Campos; Flavia O Costa; Manuel H Aguiar-Oliveira
Journal:  Endocrine       Date:  2013-02-10       Impact factor: 3.633

7.  Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats.

Authors:  Michael Ezrokhi; Shuqin Luo; Yelena Trubitsyna; Anthony H Cincotta
Journal:  Diabetol Metab Syndr       Date:  2014-09-25       Impact factor: 3.320

Review 8.  Glucose Abnormalities Associated to Prolactin Secreting Pituitary Adenomas.

Authors:  Renata S Auriemma; Dario De Alcubierre; Rosa Pirchio; Rosario Pivonello; Annamaria Colao
Journal:  Front Endocrinol (Lausanne)       Date:  2019-05-22       Impact factor: 5.555

9.  Effects of Pituitary Surgery and High-Dose Cabergoline Therapy on Metabolic Profile in Patients With Prolactinoma Resistant to Conventional Cabergoline Treatment.

Authors:  Rosa Pirchio; Renata S Auriemma; Domenico Solari; Mauro Arnesi; Claudia Pivonello; Mariarosaria Negri; Cristina de Angelis; Luigi M Cavallo; Paolo Cappabianca; Annamaria Colao; Rosario Pivonello
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-30       Impact factor: 5.555

10.  Time-of-Day-Dependent Effects of Bromocriptine to Ameliorate Vascular Pathology and Metabolic Syndrome in SHR Rats Held on High Fat Diet.

Authors:  Michael Ezrokhi; Yahong Zhang; Shuqin Luo; Anthony H Cincotta
Journal:  Int J Mol Sci       Date:  2021-06-07       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.